Two Memorial Sloan-Kettering studies that hold promise for the treatment of advanced uveal (eye) melanoma and advanced skin melanoma are making headlines at the 49th Annual Meeting of the American Society of Clinical Oncology.

Two clinical trials of targeted therapies led by Memorial Sloan-Kettering investigators show promising results against different types of sarcoma.

Early research led by investigators at Memorial Sloan-Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Memorial Sloan-Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Study signals hope for maintaining sexual function in men undergoing radiation treatment for prostate cancer.

Results of an international study indicate that the investigational drug tivozanib is more effective and better tolerated than a currently approved therapy in delaying cancer growth.